ArticleScientific reports2025
History of injection drug use in the month preceding incarceration in Iranian prisons.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study aimed to investigate the prevalence and pattern of injecting drug use (IDU) in Iranian incarcerated people one month before their imprisonment. This cross-sectional study used data from the national Bio-Behavioral Surveillance Surveys conducted from a random sample of people incarcerated in 33 prisons covering the major geographical areas of Iran in 2017 (n = 5,785). A multivariable logistic regression model was used to determine factors related to IDU one month before imprisonment. The lifetime prevalence of IDU among Iranian incarcerated people was 12.2% (95% confidence interval [CI] 11.4, 13.1), of whom 19.2% (95% CI16.3, 22.3) injected in the month before imprisonment. Among incarcerated people with a lifetime history of IDU, the average age at which they started IDU was 24.5 ± 5.9 years, and the mean injection duration was 36.8 months (95% CI 33.5, 40.1). Friends were the initial influence for starting IDU in 67.7% of cases. Additionally, 58.6% of incarcerated people with a history of IDU used a new syringe/needle for injections in the month before imprisonment. Participants over 40 years old were less likely to inject in the month before incarceration than the 18-to-29-year age group (adjusted odds ratio [AOR] 0.37, 95% CI 0.19, 0.73). A history of previous imprisonment (AOR 2.17, 95% CI 1.27, 3.70) and having a tattoo (AOR 1.75, 95% CI 1.15, 2.68) showed significant positive associations with IDU in the month before imprisonment. The study found that one in eight persons detained in Iran had a history of IDU, of whom one in five injected in the month before incarceration with higher rates among persons with younger age, tattoos, and previous incarceration. Implementing targeted prevention programs within prisons, including better access to rehabilitation and needle exchange programs, is recommended to reduce the risks of infectious disease transmission including HIV and HCV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.